Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 12/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | IKBKE | Q14164 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17630232 | 0.88 | TBK1 (0.44) | TBK1JAK2IKBKE | |
| SCHEMBL17630235 | 0.88 | TBK1 (0.44) | TBK1JAK2IKBKE | |
| SCHEMBL17289929 | 0.86 | TBK1 (0.46) | TBK1JAK2IKBKE | |
| SCHEMBL1667546 | 0.85 | TBK1 (0.51) | TBK1IKBKE | |
| SCHEMBL24860958 | 0.83 | XDH (0.47) | TBK1MAOAMAOBSLC6A4IKBKE | |
| SCHEMBL15716135 | 0.83 | XDH (0.44) | TBK1MAOAMAOBSLC6A4IKBKE | |
| SCHEMBL15320457 | 0.81 | KDM4E (0.54) | TBK1JAK2IKBKE | |
| SCHEMBL29846992 | 0.81 | TBK1 (0.40) | TBK1JAK2IKBKE | |
| SCHEMBL16075152 | 0.81 | SYK (0.40) | TBK1JAK2IKBKE | |
| SCHEMBL23753850 | 0.81 | TBK1 (0.40) | TBK1JAK2IKBKE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3152210-B1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-3517536-B1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3517536-A1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| US-10259811-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-10253019-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20190016717-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-01-17 | — | — | US | disclosed |
| US-20180370955-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2018-12-27 | — | — | US | disclosed |
| US-10072001-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2018-09-11 | — | — | US | disclosed |
| US-10040781-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| EP-2794602-B1 | 3-CYANARYL-1H-PYRAZOLO(2.3-B) PYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-11-29 | — | — | EP | disclosed |
| US-20150344473-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2015-12-03 | — | — | US | disclosed |
| US-9102675-B2 | 3-Cyanoaryl-1H-pyrrolo[2,3-B] pyridine derivatives | MERCK PATENT GMBH (DE) | 2015-08-11 | — | — | US | disclosed |
| US-9102675-B2 | 3-Cyanoaryl-1H-pyrrolo[2,3-B] pyridine derivatives | MERCK PATENT GMBH (DE) | 2015-08-11 | — | — | US | disclosed |
| US-9102675-B2 | 3-Cyanoaryl-1H-pyrrolo[2,3-B] pyridine derivatives | MERCK PATENT GMBH (DE) | 2015-08-11 | — | — | US | disclosed |
| US-20140323481-A1 | 3-CYANOARYL-1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323481-A1 | 3-CYANOARYL-1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323481-A1 | 3-CYANOARYL-1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-10-30 | — | — | US | disclosed |
| EP-2794602-A1 | 3-CYANARYL-1H-PYRAZOLO(2.3-B) PYRIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013075785-A1 | 3-CYANARYL-1H-PYRAZOLO[2.3-B]PYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-05-30 | — | — | WO | disclosed |
| WO-2013075785-A1 | 3-CYANARYL-1H-PYRAZOLO[2.3-B]PYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180370955-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | TBK1 4/4885JAK2 750/4885MAOA 4641/4885 |
| US-20150344473-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | TBK1 4/4885JAK2 750/4885MAOA 4641/4885 |
| US-10259811-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | TBK1 4/4885JAK2 750/4885MAOA 4641/4885 |
| US-10253019-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | TBK1 4/4885JAK2 750/4885MAOA 4641/4885 |
| US-10040781-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | TBK1 4/4885JAK2 750/4885MAOA 4641/4885 |
| US-10072001-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | TBK1 4/4885JAK2 750/4885MAOA 4641/4885 |
| US-20190016717-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | TBK1 4/4885JAK2 750/4885MAOA 4641/4885 |
| US-20140323481-A1 | 3-CYANOARYL-1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES | TBK1, NFKBIA, IKBKG | TBK1 1/4885JAK2 67/4885MAOA 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.